A phase 3 clinical trial, CheckMate-9LA, evaluating Bristol-Myers Squibb’s Opdivo (nivolumab) + low-dose Yervoy (ipilimumab), together with two cycles of chemo, for the first-line treatment of advanced non-small cell lung cancer met the primary endpoint of overall survival compared to chemo alone for up to four cycles followed by optional maintenance therapy.
Speaking on The Cancer Letter Podcast, Taofeek Kunle Owonikoko recalled recent conversations with two junior faculty members at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
